Background: Vincristine is one of the cornerstones of the treatment of children with acute lymphoblastic leukaemia (ALL). Constipation, and peripheral and central neurotoxicities are the most common side effects. A comparative study exploring vincristine toxicity in individual patients receiving vincristine with and without azoles, however, is lacking.
Introduction
Multiagent intensive chemotherapy for children with acute lymphoblastic leukaemia (ALL) includes vincristine as one of the main drugs. Neurotoxicity is the dose-limiting side effect, resulting in a narrow therapeutic index for vincristine. 1, 2 Vincristine is metabolized by the CYP3A subfamily and is transported by the multidrug resistance (MDR) transporter P-glycoprotein (P-gp). 2 The triazole antifungal agents fluconazole, voriconazole, itraconazole and posaconazole are commonly used for prophylaxis and for the treatment of invasive fungal infections. Over the last two decades, the frequency and severity of fungal infections have increased in paediatric patients due to more intensive chemotherapy, prompting the use of antifungal therapy. 3 -5 Based on the increased incidence of fungal infections, itraconazole prophylaxis [5 mg/kg once daily (oral suspension)] during phases of neutropenia was recommended by the current Dutch Childhood Oncology Group (DCOG), International Berlin Frankfurt Munster (IBFM)-based ALL-10 protocol. The downside of the use of azole antifungal drugs is that they interact with the metabolism of vincristine. Some of the triazoles may, furthermore, inhibit P-gp. The interaction of azole drugs with vincristine may potentiate the side effects of vincristine. 6, 7 In the literature, some case reports describe enhanced vincristine toxicity with co-administration of the azoles. 8 However, a comparative study comparing vincristine-induced toxicity within individual patients, during a treatment phase with and without azoles, is lacking. Therefore, we retrospectively analysed vincristine-induced toxicity in periods with and without the co-administration of azoles (prophylaxis and treatment) in 20 individual patients with childhood ALL.
Methods

Patients and study design
Patients treated according to the current DCOG, IBFM-based ALL-10 protocol and who simultaneously received azole therapy were included in our study. The azole therapy consisted of prophylaxis with itraconazole or treatment with fluconazole or voriconazole.
The DCOG ALL-10 protocol comprises an induction phase, followed by high-dose methotrexate. For post-induction treatment, patients were stratified in either a standard-risk (SR), medium-risk (MR) or high-risk (HR) group, based on the presence of high-risk criteria and/or their response to treatment. The vincristine schedule of the ALL-10 protocol is shown in Table 1 . In each patient, vincristine toxicity was retrospectively graded in a period with and without azole co-medication.
The phase of chemotherapeutic treatment in which the antifungal therapy was administered differed between patients (Table 2) .
Toxicity assessment
The toxicity of vincristine was graded retrospectively according to the US National Cancer Institute toxicity scale (http://ctep.cancer.gov/ protocoldevelopment/electronic_applications/docs/ctcaev3). A blinded and independent investigator performed the toxicity assessment. For vincristine-related toxicity, constipation, peripheral neurotoxicity (motor and sensory neuropathy) and CNS toxicity were evaluated.
Statistical analyses
The Wilcoxon signed rank and McNemar's tests were used for pair-wise comparisons.
The non-parametric Wilcoxon signed rank test was used for comparisons of the toxicity grade for peripheral neurotoxicity and constipation. CNS toxicity comparisons of the dichotomous variables between vincristine alone and vincristine plus an azole agent were performed using a paired McNemar's test. All statistical tests were two-sided and P,0.05 was used to indicate statistical significance. Data were analysed by SPSS 16.0 (SPSS, Chicago, IL, USA).
Results
Patients
Twenty paediatric patients received azole therapy simultaneously with vincristine and were included in this study. After stratification, 1 patient was treated according to the SR Treatment duration is without maintenance treatment with 6-mercaptopurine and methotrexate. ITC  prophylaxis  induction  0  0  0  3  6  ITC  prophylaxis  induction  0  2  0  3  7  ITC  prophylaxis  medium risk  1  2  1  3  8   b   ITC  prophylaxis  medium risk  2  2  0  2  9  ITC  prophylaxis  medium risk  1  1  0  2  10   b   ITC  prophylaxis  medium risk  0  0  0  2  11  ITC  prophylaxis  medium risk  0  0  1  2  12  ITC  prophylaxis  medium risk  1  2  0  3  13  ITC  prophylaxis  medium risk  0  0  2  3  14   b   ITC  prophylaxis  medium risk  1  2  0  2  15  ITC  prophylaxis  medium risk  0  1  0  2  16   b   ITC  prophylaxis  medium risk  2  3  0  3  17  ITC  prophylaxis  medium risk  1  3  0  3  18   b   ITC  prophylaxis  medium risk  1  3  2  3  19  VRC  CNS fungal infection  high risk  0  1  0  3 van Schie et al.
regimen, 16 patients to the MR regimen and 3 patients to the HR regimen. One patient received induction treatment according to the DCOG ALL-10 protocol and was then changed to the DCOG ALL-9 protocol, 9 because treatment was complicated by a systemic yeast infection. According to the DCOG ALL-9 protocol, vincristine (2 mg/m 2 ) was administered every 6 weeks during 81 weeks of treatment. Table 2 shows in which phase of the treatment patients received azole therapy in combination with vincristine. Sixteen patients received itraconazole prophylaxis at 5 mg/kg once daily. Three patients received intravenous voriconazole at a dose of 7 mg/kg twice daily as empirical or diagnostic-driven treatment. One of these patients was switched to itraconazole as secondary prophylaxis after resolution of symptoms. One patient with a systemic yeast infection received 5 mg/kg fluconazole once daily. The duration of the azole treatment ranged from 1 to 9 weeks.
Toxicity assessment
In the period during which patients were treated with vincristine in combination with azoles, they complained significantly more of constipation (P¼ 0.001) and peripheral neurotoxicity (P,0.001) than in the period in which they received vincristine without azoles (Table 2 ). Six patients experienced at least grade 3 constipation toxicity when treated with an azole agent. Of them, five received itraconazole prophylaxis and one patient was treated with fluconazole. Twelve patients developed at least grade 3 peripheral neurotoxicity; this occurred in 10 patients after itraconazole prophylaxis was started and in 2 patients after the administration of voriconazole. Neurotoxicity of at least grade 3 was not noted in patients while they were treated with vincristine without azole therapy. Three patients developed severe peripheral neurotoxicity while vincristine was co-administered with itraconazole and needed an admission to the paediatric intensive care unit for opiate analgesic medication. None of the patients died as a consequence of vincristine toxicity.
Vincristine-induced CNS toxicity was seen in six patients. All of these patients received itraconazole prophylaxis in combination with vincristine. CNS toxicity was not observed while patients received vincristine without azoles (P ¼0.014). Of six patients with CNS toxicity, two patients experienced multiple occasions of convulsions, two patients were diagnosed with vincristinerelated toxic encephalopathy and two patients were affected by the syndrome of inappropriate secretion of antidiuretic hormone. In all children, progressive improvement was noted after discontinuation of the azole treatment.
Discussion
To our knowledge, this is the first comparative study comparing the toxicity, within individual patients, in a treatment phase in which the patients received vincristine and azoles, with the toxicity in a treatment phase in which the same patients received vincristine without azoles. Our study showed that vincristine toxicity was enhanced significantly by the concomitant use of azole antifungal therapy.
All toxicity parameters that were measured increased in the period when patients received vincristine in combination with azole agents. For peripheral neuropathy the toxicity grade was significantly higher in all patients when azoles were co-administered with vincristine. Although differences in the severity of neurotoxicity can be explained by the co-administration of azoles, the cumulative dose of vincristine administered to the patients probably also plays a role. CNS toxicity was only observed in the period vincristine was combined with azoles. Significant improvement of neurotoxicity was noted after discontinuation of the azole treatment in all children.
The azole agents were administered in different phases of ALL treatment, during which different chemotherapeutic agents other than vincristine were used. Enhanced vincristine neurotoxicity was seen, irrespective of the phase of therapy (e.g. induction, consolidation and maintenance treatment) when azole agents were used. Therefore, the involvement of other chemotherapeutic agents in the enhancement of neurotoxicity seems unlikely, but an additive effect could not be ruled out completely.
Based on the risk of developing severe fungal infections, the current DCOG, IBFM-based ALL-10 protocol prescribed itraconazole antifungal prophylaxis during the intensive phases of the ALL chemotherapeutic treatment. Although there are some case reports describing enhanced toxicity of vincristine when co-administered with azole therapy, serious complications were not expected when we started with antifungal prophylaxis in the ALL-10 protocol.
In this study, the majority of patients (n¼ 16) received itraconazole prophylaxis. All azoles inhibit the CYP3A4 isoenzyme. 2 Based on the potency of the enzyme inhibition, less enhancement of vincristine toxicity would be expected when vincristine is combined with fluconazole or voriconazole than with itraconazole. In addition, fluconazole and voriconazole do not inhibit P-gp, whereas it has been suggested that itraconazole can inhibit the pump. However, the vincristine toxicity grade for constipation and peripheral neurotoxicity also increased in patients in whom fluconazole and voriconazole were co-administered with vincristine, but a comparison of the severity of vincristine toxicity caused by different azoles cannot be performed due to the small numbers of patients ( Table 2) .
The efficacy of itraconazole was previously limited by poor absorption from the gastrointestinal tract. The bioavailability of itraconazole has been increased by using an oral suspension. Still, it would be advisable to monitor itraconazole plasma concentrations to investigate the exposure-toxicity relationship. The itraconazole plasma concentration was not monitored in our patients. However, since itraconazole enhanced vincristine toxicity in all patients, irrespective of the phase of therapy, and reversibility in toxicity occurred after cessation of itraconazole, we expect a high inhibitory potential even at low concentrations.
As described before, the human CYP3A and MDR genes are highly polymorphic. 10 Genetically polymorphic enzymes involved in the metabolism of vincristine might be an additional explanation for the interpatient variability in vincristine neurotoxicity. 10 However, genetic polymorphisms did not influence our results, as comparisons were made within individuals. Intensive monitoring of the vincristine plasma concentration might be another option in preventing toxicity, but the relation between vincristine plasma levels and toxicity remains debatable.
In conclusion, this study shows that vincristine toxicity is significantly increased and can even be life threatening when vincristine is combined with azole treatment, especially Increased vincristine toxicity due to azole treatment 1855 JAC itraconazole. Combination should therefore be avoided or, at least, be critically monitored.
